Amendments to the Claims:

Please amend claims 1, 3, 6, 7, 10-13, 34-36 and 38-41, cancel claims 2, 4-5, and 14-33, and add new claims 42-48. This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 (currently amended): A method for ~~modulating~~ reducing expression of a mammalian SREBP-1 gene by administering ~~a modulator compound that promotes or~~ an antagonist of LXRα that inhibits LXRα-mediated expression of the SREBP-1 gene to a cell that comprises an SREBP-1 gene and an LXRα polypeptide, wherein said antagonist is an oxysterol.

2 (canceled).

3 (currently amended): The method of claim 1, wherein the ~~modulator compound promotes or~~ antagonist inhibits LXRα-mediated expression of the SREBP-1c transcript.

4 (canceled).

5 (canceled).

6 (currently amended): The method of claim ~~5~~ 1, wherein the cell further comprises one or more genes that encode an enzyme involved in fatty acid and triglyceride metabolism and contacting the cell with the ~~modulator compound~~ antagonist inhibits expression of one or more of the genes that encode an enzyme involved in fatty acid and triglyceride metabolism.

7 (currently amended): The method of claim ~~1~~ 6, wherein the enzyme involved in fatty acid and triglyceride metabolism is selected from the group consisting of fatty acid synthase, acetyl CoA carboxylase, steroyl CoA desaturase, and lipoprotein lipase.

8 (original): The method of claim 1, wherein the cell is in a mammal.

9 (original): The method of claim 8, wherein the mammal is a human.

10 (currently amended): The method of claim 8, wherein ~~the modulator compound is an antagonist of LXRα and~~ triglyceride levels in the mammal are reduced.

11 (currently amended): The method of claim 8, wherein ~~the modulator compound is an antagonist of LXRα and~~ insulin levels in the mammal are reduced.

12 (currently amended): A method of modulating triglyceride levels in a mammal, the method comprising administering to the mammal an effective amount of a modulator compound that comprises at least one of LXRα antagonist and LXRα agonist activity that promotes or inhibits LXRα-mediated expression of an SREBP-1 gene in cells of the mammal, wherein the modulator compound is an oxysterol.

13 (currently amended): The method of claim 12, wherein the mammal is a human.

14-33 (canceled)

34 (currently amended): A method for ameliorating a condition associated with ~~abnormal~~ abnormally high SREBP-1 expression in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a LXRα antagonist, wherein said antagonist is an oxysterol.

35 (currently amended): The method of claim 34, wherein the condition associated with ~~abnormal~~ abnormally high SREBP-1 expression is hypertriglyceridemia.

36 (currently amended): The method of claim 34, wherein the condition associated with ~~abnormal~~ abnormally high SREBP-1 expression is lipodystrophy.

37 (original): The method of claim 36, wherein the lipodystrophy is congenital generalized lipodystrophy.

38 (currently amended): The method of claim 34, wherein the condition associated with ~~abnormal~~ abnormally high SREBP-1 expression is insulin resistance.

39 (currently amended): The method of claim 34, wherein the condition associated with ~~abnormal~~ abnormally high SREBP-1 expression is an elevated plasma insulin level.

40 (currently amended): The method of claim 34, wherein the condition associated with ~~abnormal~~ abnormally high SREBP-1 expression is hyperglycemia and/or diabetes mellitus.

41 (currently amended): The method of claim 34, wherein the condition associated with ~~abnormal~~ abnormally high SREBP-1 expression is a syndrome associated with treatment of AIDS by administration of an HIV protease inhibitor, which syndrome is characterized by one or more of lipodystrophy, insulin resistance and hyperlipidemia.

42. (new): The method of claim 34, wherein the condition associated with abnormally high SREBP-1 expression is pancreatitis.

43. (new): The method of claim 12, wherein the modulator compound is an agonist of LXRα and promotes LXRα-mediated expression of the SREBP-1 gene.

44 (new): The method of claim 12, wherein the modulator compound promotes or inhibits LXRα-mediated expression of the SREBP-1c transcript.

45 (new): The method of claim 43, wherein the modulator compound is 24,25-epoxycholesterol.

46 (new): The method of claim 12, wherein the modulator compound is an antagonist of LXRα and inhibits LXRα-mediated expression of the SREBP-1 gene.

47. (new): A method of increasing triglyceride levels in a mammal, the method comprising administering to the mammal an effective amount of an agonist of LXRα that promotes LXRα-mediated expression of an SREBP-1 gene in cells of the mammal.

48. (new): The method of claim 47, wherein the agonist is selected from the group consisting of an oxysterol, *N*-methyl-*N*-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide (T0314407), N-(2,2,2-trifluoro-ethyl)-*N*-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide (T0901317), and mixtures thereof.

49. (new): A method of decreasing triglyceride levels in a mammal, the method comprising administering to the mammal an effective amount of an antagonist of LXRα that inhibits LXRα-mediated expression of an SREBP-1 gene in cells of the mammal, wherein the modulator compound is an oxysterol.